FOSAMPRENAVIR CALCIUM

Post-LOE

fosamprenavir calcium

Viatris (2)

ANDAORALTABLET

Approved

Apr 2016

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

FOSAMPRENAVIR CALCIUM (fosamprenavir calcium) by Viatris (2) is hiv-1 antiretroviral agent [see ] . Approved for combination with other antiretroviral agents for the treatment of hiv-1 infection. First approved in 2016.

Drug data last refreshed 22h ago

Mechanism of Action

HIV-1 antiretroviral agent [see ] .

Indications (1)

combination with other antiretroviral agents for the treatment of HIV-1 infection

Company

Worked on FOSAMPRENAVIR CALCIUM at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.